<DOC>
	<DOCNO>NCT00605293</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety monthly administration intravenous ( IV ) Mircera versus epoetin alfa maintenance hemoglobin level hemodialysis patient chronic renal anemia . Participants currently receive maintenance treatment epoetin alfa randomize either receive monthly injection 120 , 200 360 microgram Mircera , start dose derive dose epoetin alfa receive week precede study start , continue epoetin alfa treatment . The anticipated duration study 32 week , target sample size 146 participant .</brief_summary>
	<brief_title>A Study Intravenous Mircera ( C.E.R.A Methoxy Polyethylene Glycol-epoetin Beta ) Maintenance Treatment Hemodialysis Participants With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>chronic renal anemia ; continuous iv maintenance epoetin alfa therapy , dose interval previous month SVP ; regular hemodialysis great equal ( &gt; = ) 3 month transfusion red blood cell previous 2 month poorly control hypertension require interruption epoetin alfa treatment previous 6 month ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>